Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Peptic Ulcer

Peptic Ulcer

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Peptic Ulcer

7 trials tracked for Peptic Ulcer: 3 in phase 3 or 4.

7Trials tracked
3Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 1 Other / NA 3
  1. Phase 4 Clarithromycin Resistant Tailored Therapy Completed
  2. Phase 4 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed
  3. Phase 3 Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers Completed
  4. Phase 2 Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer Completed
  5. N/A Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer Completed
  6. N/A Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers Completed
Show 1 more trials
  1. N/A Feasibility of Translumenal Endoscopic Omental Patch Closure of Perforated Viscus Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance
Gastroenterology Sys. Review
Bismuth quadruple and concomitant regimens achieve >85% H. pylori eradication amid rising clarithromycin resistance H. pylori treatments failing as resistance grows, review finds
This narrative review synthesizes current H. pylori eradication strategies, noting that clarithromycin resistance exceeds 15%-20% in most re…
Clarithromycin resistance now tops 15-20% in most regions, but bismuth quadruple and other combos still clear the bug over 85% of the time.
Frontiers Jul 29, 2026
H. pylori eradication reduces gastric cancer risk by up to 44%, per guideline review
Gastroenterology Guideline
H. pylori eradication reduces gastric cancer risk by up to 44%, per guideline review Review finds H. pylori eradication reduces risk of stomach cancer and ulcers
A narrative review of global evidence indicates H.
Treating a common stomach bacteria infection can lower future cancer risk by up to 44% and prevent recurring ulcers.
Frontiers Apr 3, 2026